Tyrzette is an indigenous analog of American Mounjaro. Both drugs are based on an innovative molecule and do not contain preservatives. According to Promoted, approximately 40 million people suffer from obesity in Russia, 60 million more weight. This increases the risks of cardiovascular disease and oncology.
As explained by the marketing director Lyudmila Kovalchuk, the endocrinology direction, an increase in the optimization and release volume of costs made it possible to make treatment more appropriate. The new price is valid for the entire line of the drug since May 6.
Tyrzette appeared in the market in February 2024. Production corresponds to the duties of import substitution in drugs. Reduction of cost is particularly important for patients who need a long treatment process.
News -law materials cannot be equalized to the doctor’s prescription. Consult a specialist before deciding.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
